Adocia S.A.S. American Depositary Receipt

Adocia S.A.S. American Depositary Receipt is a financial instrument that represents shares of Adocia S.A.S., a French clinical-stage biotechnology company, for trading in the United States. The primary function of this American Depositary Receipt is to provide U.S. investors with exposure to Adocia’s equity without the complexities associated with purchasing shares directly on foreign exchanges or dealing with foreign currencies. Adocia specializes in the development of innovative formulations based on therapeutic proteins and peptides, targeting diabetes and other metabolic diseases through its proprietary BioChaperone technology platform. Its research pipeline includes ultra-rapid insulin formulations and novel therapies in both clinical and preclinical stages, such as implantable islets and oral peptide delivery solutions. As an ADR, this asset plays a key role in enabling cross-border investment, broadening Adocia’s shareholder base, and facilitating capital access for the company within American financial markets. The ADR trades on the OTC Pink marketplace, which offers a platform for international companies to reach U.S. investors with fewer regulatory requirements compared to major exchanges.